Photodynamic Therapy Market Report 2025

The photodynamic therapy market size has grown strongly in recent years. It will grow from $1.45 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to an aging population pool, an increase in cancer prevalence, an increase in skin diseases, rising pollution rates, increased healthcare expenditure, and growth in the number of healthcare facilities.

The photodynamic therapy market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to the rise in healthcare expenditure, insurance coverage for photodynamic therapy, high potential in emerging economies, increasing teenage population, increasing older population, increasing prevalence of cancer and chronic diseases, and the emergence of infectious diseases. Major trends in the forecast period include the introduction of a portable photodynamic therapy device that helps in at-home dermatological PDT treatments, investing in artificial intelligence-enabled PDT for improved treatment of patients, expanding the product portfolio in cosmetic procedures, continuing investment in research and development, focusing at providing photoimmunotherapy devices and expand the portfolio to include photothermal therapy.

The rising incidence of skin cancer is driving the growth of the photodynamic therapy (PDT) market. Skin cancer is recognized as the most common form of cancer, with melanoma accounting for about 1% of cases but leading to a significant number of skin cancer-related deaths. PDT involves using a light-sensitizing medication combined with intense light to target and destroy cancer cells. This process typically begins with a doctor applying a lotion containing the light-sensitizing agent to the skin cancer and its surrounding area. For example, in January 2024, the American Cancer Society, a U.S.-based professional organization, reported that skin cancer is the most prevalent cancer in the U.S. Melanoma, while only 1% of cases, is responsible for the majority of skin cancer fatalities. Additionally, it is estimated that in 2024, there will be about 100,640 new melanoma diagnoses in the U.S., with approximately 59,170 cases in men and 41,470 in women. Around 8,290 deaths from melanoma are projected, including about 5,430 men and 2,860 women. Consequently, the increasing prevalence of skin cancer is anticipated to significantly boost the growth of the photodynamic therapy market in the coming years.

The rising healthcare expenditure is anticipated to boost the growth of the photodynamic therapy (PDT) market in the future. Healthcare expenditure encompasses the total funds allocated for healthcare goods and services, including medical equipment, hospital services, physician services, prescription drugs, and public health initiatives. This expenditure is vital for advancing photodynamic therapy as it facilitates research, education, infrastructure development, and patient access. For instance, in June 2024, The King's Fund, a UK-based non-profit organization, reported that in 2022/23, the Department for Health and Social Care allocated £182 billion ($227.5 billion) to support various health and care services, including GP services, ambulance services, mental health, community care, and hospital care. Furthermore, the budget for the 2024/25 period is projected to increase to £192 billion ($240 billion), reflecting a rise of £1.1 billion ($1.375 billion) from the previous year, even after accounting for inflation. This funding is aimed at enhancing the quality and accessibility of health services, indicating a strong commitment to improving healthcare resources. Therefore, the growing healthcare expenditure is driving the expansion of the photodynamic therapy market.

Key players in the photodynamic therapy (PDT) market are increasingly emphasizing clinical trials that explore the combination of PDT with various drugs. For example, in February 2024, Kintara Therapeutics, a US-based biotechnology company, announced the launch of a clinical trial for its REM-001 therapy, which targets cutaneous metastatic breast cancer. The clinical trial, identified as NCT05374915, is an open-label study involving 15 patients diagnosed with cutaneous metastatic breast cancer (CMBC). It aims to evaluate the efficacy of the second-generation photodynamic therapy agent REM-001 at a dosage of 0.8 mg. The trial seeks to refine the study design in preparation for a Phase 3 trial and focuses on the Best Overall Objective Response Rate (bORR) in treatment fields over a 24-week period. The primary endpoints include the assessment of complete and partial responses to the treatment.

Artificial intelligence models have demonstrated significant potential in the diagnosis and treatment of cancer. There is an increasing trend in funding aimed at enhancing product design and clinical testing, particularly in the realm of artificial intelligence applications in photodynamic therapy (PDT). AI is being utilized to examine pain and outcomes for superficial basal cell carcinomas and other diseases treated with PDT. For example, in June 2024, Biofrontera Inc., a biopharmaceutical company based in the US, introduced its FDA-approved RhodoLED XL lamp for the treatment of actinic keratosis. The FDA has authorized a new device to be used in conjunction with aminolevulinic acid hydrochloride topical gel (Ameluz) as a PDT option for mild-to-moderate actinic keratoses on the face and scalp. The RhodoLED XL commenced commercial distribution in June 2024, showcasing the company's dedication to innovation in dermatology. Its user-friendly design and features are intended to improve patient care and may set a new benchmark for PDT. The announcement emphasized the considerable advancements this lamp provides for the treatment of actinic keratosis, the most prevalent pre-cancerous skin condition.

In February 2023, Omni Partners LLP, a UK-based investment management firm, finalized the acquisition of Aesthetic Technology Ltd for an undisclosed sum. This acquisition is part of Omni Partners' strategy to enhance new technologies in healthcare, particularly those that offer effective solutions for aesthetic and medical treatments. Aesthetic Technology Limited is a UK-based manufacturer of medical equipment, focusing on innovative energy-based devices for the medical, aesthetic, and cosmetic sectors.

Major companies operating in the photodynamic therapy market include Galderma S.A., Bausch Health, Lumenis Ltd., Sun Pharmaceutical Industries Ltd., Biofrontera, Modlight Inc., PhotoMedex Inc., Soligenix Inc., Quest PharmaTech Inc., Novartis AG, Theralase Technologies Inc., Quantel Medical, Axcan Pharma, Sihealth, MediGlobus, Steba Biotech, Ambicare Health, Nuovo Therapy, Pharmstandard, Rusatom Healthcare, Roche Latvija SIA, Hologic, Inc., Dusa Pharmaceuticals, PDT Pharma Indústria e Comércio de ProdutosFarmacêuticos, MMOptics Ltd, Global Healthcare Solutions Perú, DMC Equipmentos LTDA, Biolite, SyMed LLC, Alma Lasers, Candela Medica, Velt International Group Inc.

North America was the largest region in the photodynamic therapy market in 2024. The regions covered in the photodynamic therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the photodynamic therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Photodynamic therapy (PDT) is a procedure that involves using a light source and light-sensitive medication to eliminate abnormal cells. It is applied in the treatment of certain eye and skin disorders, as well as specific types of cancers. PDT is a two-stage treatment process that combines light energy with a light-activated drug (photosensitizer) designed to destroy cancerous and precancerous cells.

The primary product categories in the photodynamic therapy market are drugs and devices. PDT drugs are light-sensitive substances that, when activated by specific types of light, work to destroy abnormal cells for the treatment of various diseases. PDT devices include lamps, LED devices, and other light-emitting devices used to activate PDT drugs. Photodynamic therapy finds applications in treating diseases such as acne, actinic keratosis, cancer, and psoriasis, among others. It is employed in various sectors, including cosmetics and dermatology clinics, hospitals, cancer treatment centers, and others.

The photodynamic therapy market research report is one of a series of new reports that provides photodynamic therapy market statistics, including photodynamic therapy industry global market size, regional shares, competitors with a photodynamic therapy market share, detailed photodynamic therapy market segments, market trends and opportunities, and any further data you may need to thrive in the photodynamic therapy industry. This photodynamic therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The photodynamic therapy market includes revenues earned by entities by treating actinic keratoses and superficial basal cell carcinomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.